• Home
  • NEW DAY MEDICINE
  • 6 (92) 2026
  • 90 -6 (92) 2026 - Shodmonov I.S., Oblokulov A.R., Mukhammadieva M.I. - THE IMPORTANCE OF THE COURSE OF COVID - 19 IN PATIENTS WITH CARDIOVASCULAR DISEASES

90 -6 (92) 2026 - Shodmonov I.S., Oblokulov A.R., Mukhammadieva M.I. - THE IMPORTANCE OF THE COURSE OF COVID - 19 IN PATIENTS WITH CARDIOVASCULAR DISEASES

THE IMPORTANCE OF THE COURSE OF COVID - 19 IN PATIENTS WITH CARDIOVASCULAR DISEASES

Shodmonov I.S., Oblokulov A.R., Mukhammadieva M.I. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

SARS-CoV-2 virus-induced infection can occur in symptom-free or mild form, as well as severe form with a high risk of death, but the full clinical picture is not yet clear. Symptoms can appear on about 5-6 days of damage, while the period of stagnation can be 1-14 days. Also, the fact that the ratio of these immunological markers is a criterion that predicts the level of clinical severity and negative consequences of comorbid disease (concomitant course of coronavirus and cardiac pathology) in patients is presented through the results of a medical study.

Keywords: COVID-19, cardiovascular diseases, clinical course, complications, prognosis.

First page

531

Last page

534

For citation: Shodmonov I.S., Oblokulov A.R., Mukhammadieva M.I. - THE IMPORTANCE OF THE COURSE OF COVID - 19 IN PATIENTS WITH CARDIOVASCULAR DISEASES//New Day in Medicine 6(92)2026 531-534 https://newdayworldmedicine.com/en/new_day_medicine/6-92-2026

List of References

  1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3.
  2. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811-818. doi:10.1001/jamacardio.2020.1017.
  3. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802-810. doi:10.1001/jamacardio.2020.0950.
  4. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and cardiovascular disease. Circulation. 2020;141(20):1648-1655. doi:10.1161/CIRCULATIONAHA.120.046941.
  5. Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020;14(3):247-250. doi:10.1016/j.dsx.2020.03.013.
  6. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020;5(7):831-840. doi:10.1001/jamacardio.2020.1286.
  7. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75(18):2352-2371. doi:10.1016/j.jacc.2020.03.031.
  8. Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Prog Cardiovasc Dis. 2020;63(3):390-391. doi:10.1016/j.pcad.2020.03.001.
  9. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847. doi:10.1111/jth.14768.
  10. European Society of Cardiology. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic. Eur Heart J. 2020;41(19):1805-1807. doi:10.1093/eurheartj/ehaa258.
  11. World Health Organization. Clinical management of COVID-19: interim guidance. Geneva: World Health Organization; 2020.

    file

    download